Assembly Biosciences
Assembly Bio is a biopharmaceutical company dedicated to developing innovative therapeutics that target serious viral diseases, including herpesviruses, hepatitis delta virus (HDV), and hepatitis B virus (HBV). With a focus on scientific ingenuity and patient impact, the company aims to change the treatment paradigm for these infections through its pipeline of clinical and research programs.
Industries
Nr. of Employees
medium (51-250)
Assembly Biosciences
Carmel, Indiana, United States, North America
Products
ABI-5366
Orally bioavailable helicase‑primase inhibitor developed as a long‑acting small molecule for treatment of recurrent genital herpes; Phase 1a/1b studies include pharmacokinetic characterization showing extended half‑life supporting once‑weekly or potentially once‑monthly dosing.
ABI-1179
Oral helicase‑primase inhibitor for recurrent genital herpes with preclinical characterization and Phase 1a data indicating a multi‑day half‑life consistent with once‑weekly dosing; preparing for Phase 1b studies.
ABI-4334
Next‑generation orally bioavailable capsid assembly modulator designed to disrupt HBV capsids and inhibit replenishment of cccDNA; under clinical evaluation in Phase 1/1b studies.
ABI-6250
Orally bioavailable small‑molecule entry inhibitor that targets the NTCP receptor to block hepatitis D virus (HDV) infection; characterized in preclinical studies and advancing through early clinical evaluation.
ABI-5366
Orally bioavailable helicase‑primase inhibitor developed as a long‑acting small molecule for treatment of recurrent genital herpes; Phase 1a/1b studies include pharmacokinetic characterization showing extended half‑life supporting once‑weekly or potentially once‑monthly dosing.
ABI-1179
Oral helicase‑primase inhibitor for recurrent genital herpes with preclinical characterization and Phase 1a data indicating a multi‑day half‑life consistent with once‑weekly dosing; preparing for Phase 1b studies.
ABI-4334
Next‑generation orally bioavailable capsid assembly modulator designed to disrupt HBV capsids and inhibit replenishment of cccDNA; under clinical evaluation in Phase 1/1b studies.
ABI-6250
Orally bioavailable small‑molecule entry inhibitor that targets the NTCP receptor to block hepatitis D virus (HDV) infection; characterized in preclinical studies and advancing through early clinical evaluation.
Services
Research collaborations and partnership programs
Collaborative preclinical and clinical research agreements, including option and co‑promotion arrangements, for development of antiviral therapeutics.
Clinical trial conduct and participant enrollment
Execution of early‑phase clinical studies and provision of information/resources for potential trial participants.
Research collaborations and partnership programs
Collaborative preclinical and clinical research agreements, including option and co‑promotion arrangements, for development of antiviral therapeutics.
Clinical trial conduct and participant enrollment
Execution of early‑phase clinical studies and provision of information/resources for potential trial participants.
Expertise Areas
- Clinical trial management (GCP-compliant)
- Early‑phase clinical development and PK/PD
- Antiviral small‑molecule discovery and optimization
- Capsid assembly modulation and HBV reservoir biology
Key Technologies
- Helicase‑primase inhibition
- Capsid assembly modulation (CAM)
- NTCP‑targeted entry inhibition
- Oral small‑molecule therapeutics